Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes is a chronic disease that has reached global epidemic proportions due to the
growing number of patients in all countries; It has become the disease that causes more
chronic and acute complications to patients, unfortunately, when the diagnosis of type 2
diabetes is made patients are identified at very advanced stages of the disease.
For all the above, the best strategies will be those that are aimed at early stages of the
disease, and the investigators are convinced that the use the combination of drugs with
additive pathophysiological effect plus cardiovascular protection in early stages, will have
better results, lasting and with greater results impact on the natural history of the disease
that throws measures that may have an applicability in clinical practice, in order to
contribute to the control of this pathology. Therefore, the combination of medications with
different mechanisms of action, in low doses, could be a useful strategy not only to prevent
type 2 diabetes, but also to prevent macro and microvascular complications early. The goal of
this clinical trial is to evaluate the effect of low doses of linagliptin + metformin vs
metformin alone on physiopathological parameters, such as glucose metabolism, insulin
resistance, insulin secretion and pancreatic beta cell function in patients with impaired
fasting glucose plus impaired glucose tolerance, during 12 months.